Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Advertisements

Defining the Clinical Course of Multiple Sclerosis.

Journal Insights Into: Oral Therapy for MS-Related Walking Impairment Supplemental Slides.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Personal Experiences of Progressive Multiple Sclerosis (MS)

Four Known Types of MS Clinically isolated syndrome (CIS)

Copyright © 2014 American Medical Association. All rights reserved.

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 3 Archetypal MS clinical course depicted over 20 years

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 High cervical spinal cord stimulators

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 3 Genetic pleiotropy in ALS

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Challenges for big data applications in cardiovascular care

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Urol. doi: /nrurol

Figure 1 Biomarkers associated with different clinical phases in MS

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Cellular pathways implicated in CIPN

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 2. ROC curves for different group comparisons

Figure 1 Characteristics of the German National MS Cohort

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 A large number of genes are potentially associated with CIPN

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 1 Timeline of pancreatic islet transplantation

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure Correlation between the Kurtzke Expanded Disability Status Scale and the relative expression of hsa-miR-337-3p Correlation between the Kurtzke Expanded.

Figure 1 Anti-Epstein-Barr virus nuclear antigen-1 IgG quartile antibody status differences in MRI measures Anti-Epstein-Barr virus nuclear antigen-1 IgG.

Figure 1 Levels of miR-150 are elevated in patients with multiple sclerosis (MS) and patients with clinically isolated syndrome (CIS) who convert to MS.

Figure 2 Network connections of the hypothalamus

Figure 2 Time from incident ADS event to MS diagnosis

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.171 Figure 1 Trends over time in phase III clinical trials in relapsing and progressive MS Figure 1 | Trends over time in phase III clinical trials in relapsing and progressive MS. a | The number of phase III clinical trials has greatly increased in the past 5 years, especially in relapsing multiple sclerosis (MS). Clear increases over the past 5–10 years are also evident in b | the number of end points per trial and c | the number of participants per trial. d | By contrast, trial duration has remained broadly unchanged, with most trials having a duration of 2 years or 3 years. CIS, clinically isolated syndrome; PPMS, primary progressive MS; SPMS, secondary progressive MS. Tur, C. et al. (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.171